Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO). |
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
cJK9TVAjdhb6AjYJ
